Skip to main content

Table 5 Infusions associated with tolerability concerns or AEs

From: Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

  IGSC 20 % treatment dose
145 % of IGIV Adjusted Individualized Overall
Total infusions (n) 731 867 2729 4327
Rate reduced, n (%) 1 (0.1) 4 (0.5) 0 (0.0) 5 (0.1)
Interrupted, n (%) 0 (0.0) 1 (0.1) 1 (0.0) 2(0.0)
Stopped, n (%) 0 (0.0) 0 (0.0) 1 (0.0) 1 (0.0)
No reduction, interruption or stop, n (%) 730 (99.9) 862 (99.4) 2727 (99.9) 4319 (99.8)